Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2023-07-19 | Redeye | Redeye: Enzymatica Q2 2023 - Waiting for the cold season | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-18 | Penser Access | Penser Access: Kommande studieresultat i fokus - Enzymatica | Pressreleaser | Visa Stäng |
|
||||
2023-07-18 | Enzymatica | Enzymatica AB: Kvartalsrapport Q2/2023: En spännande och viktig tid framöver | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-07-18 | Enzymatica | Enzymatica AB: Interim report Q2/2023: An exciting and important time ahead | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-16 | Penser Access | Penser Access: Interview with Enzymatica - Erik Penser Bank - May 16th 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-05-04 | Enzymatica | Bulletin from Annual General Meeting of Enzymatica AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-04 | Enzymatica | Kommuniké från årsstämma i Enzymatica AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-28 | Penser Access | Penser Access: Upp till bevis - Enzymatica | Pressreleaser | Visa Stäng |
|
||||
2023-04-28 | Redeye | Redeye: Enzymatica Q1 2023 - A step in the right direction | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-27 | Enzymatica | Enzymatica AB: Kvartalsrapport Q1/2023: Stark start på året - Enzymaticas tillväxtresa fortsätter enligt plan | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-04-27 | Enzymatica | Enzymatica AB: Interim report Q1/2023: Strong start to the year - Enzymatica's growth journey continues according to plan | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-04-05 | Enzymatica | Enzymatica AB: Enzymatica publishes annual report for 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-04-05 | Enzymatica | Enzymatica AB: Enzymatica publicerar årsredovisning för 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-03-31 | Enzymatica | Notice of Annual General Meeting 2023 in Enzymatica AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-31 | Enzymatica | Kallelse till årsstämma 2023 i Enzymatica AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-20 | Penser Access | Penser Access: Vår syn på bolagets potential är intakt - Enzymatica | Pressreleaser | Visa Stäng |
|
||||
2023-02-20 | Redeye | Redeye: Enzymatica Q4 2022 - Lower than our estimates | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-17 | Enzymatica | Enzymatica AB: Interim report Q4/2022: A year that laid the foundation for growth | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-02-17 | Enzymatica | Enzymatica AB: Kvartalsrapport Q4/2022: Ett år som lade grunden för tillväxt | Rapporter | Ladda ner | Visa Stäng |
|
||||
2022-12-06 | Redeye | Redeye: Redeye Initiates Coverage of Enzymatica | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-11-16 | Enzymatica | Enzymatica AB: Enzymatica and University of Kent launch study to explore prevention of upper respiratory virus infections in elite athletes | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Enzymatica AB: Enzymatica and University of Kent launch study to explore prevention of upper respiratory virus infections in elite athletesEnzymatica has initiated a new study into the effect of ColdZyme on the upper respiratory resilience of competitive endurance athletes – a group to which viral protection is a key priority. The study is being undertaken by the University of Kent, UK, and builds on a previous 2020 study by the same research team, showing that ColdZyme reduces the duration and symptoms of common cold in endurance athletes (e.g. triathlon, marathon, cycling). ”ColdZyme’s ability to reduce the number of lost training days could play an important role for many endurance athletes. The previous study showed athletes who used ColdZyme had milder common cold symptoms and half as many lost training days as athletes in the control group. Our new study will further explore ColdZyme’s ability to allow endurance athletes a speedier recovery from common colds and other upper respiratory virus infections”, said Professor Glen Davison, Head of School of Sport and Exercise Sciences at University of Kent. The first participants are enrolled this week, with the expectation that the full study will be presented next fall, before the cold season. The methodology is a double-blind, placebo-controlled clinical study, utilizing parallel groups design, in which participants will complete a daily training log and illness log according to the Jackson scale. Oropharyngeal swabs will be collected from both groups to identify virus strains causing the infections, as well as measuring viral load. ”We know that many groups that truly want to avoid common colds and other upper respiratory infections are great supporters of ColdZyme, be it teachers, kindergarten staff or endurance athletes. Enzymatica will launch a number of clinical trials to further investigate ColdZyme’s effect on viruses. So far, ColdZyme has been proven in vitro to block 11 different upper respiratory viruses, and we now aim to repeat these findings in vivo in clinical trials”, said Claus Egstrand, CEO of Enzymatica. More information about the study: ISRCTN – ISRCTN18133939: Does ColdZyme mouth spray protect athletes against upper respiratory tract infection? ( https://www.isrctn.com/ISRCTN18133939 ) For more information, please contact: Claus Egstrand, CEO, Enzymatica AB Stefan Olsson, Communication Manager, Enzymatica AB
Enzymatica AB develops and sells health products mainly to treat diseases and symptoms in the upper respiratory tract. The products are based on a barrier technology that includes marine enzymes with unique properties. The company’s first product is the medical device product ColdZyme®, a mouth spray for colds. The product has been launched in about 30 markets on four continents. The strategy is to continue to grow by developing more health products, strengthening the company’s position in existing markets and expanding into new geographic markets through established partners. The company is headquartered in Lund and is listed on Nasdaq First North Growth Market. For more information, please visit www.enzymatica.com. |
||||
2022-11-16 | Enzymatica | Enzymatica AB: Enzymatica och University of Kent startar studie för att undersöka hur elitidrottare kan förebygga virusinfektioner i de övre luftvägarna | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-11-03 | Penser Access | Penser Access: Inte helt ute ur coronatunneln - Enzymatica | Analyser | Visa Stäng |
|
||||
2022-11-02 | Enzymatica | Enzymatica AB: Kvartalsrapport Q3/2022: En bredare roll för ColdZyme adderar potential för framtiden | Rapporter | Ladda ner | Visa Stäng |
|
||||
2022-11-02 | Enzymatica | Enzymatica AB: Interim report Q3/2022: A broader role for ColdZyme adds potential for the future | Rapporter | Ladda ner | Visa Stäng |
|
||||
2022-11-01 | Enzymatica | Enzymatica AB: New study confirms ColdZyme stops viruses causing Covid-19 from adhering to human respiratory cells | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-11-01 | Enzymatica | Enzymatica AB: Ny studie bekräftar: ColdZyme hindrar virus som orsakar Covid-19 från att fästa vid mänskliga luftvägsceller | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-26 | Enzymatica | Enzymatica AB: Enzymatica announces outcome of new rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-26 | Enzymatica | Enzymatica AB: Enzymatica offentliggör utfall i företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-18 | Enzymatica | Enzymatica AB: Enzymatica publishes supplementary prospectus | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-18 | Enzymatica | Enzymatica AB: Enzymatica offentliggör tilläggsprospekt | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-16 | Enzymatica | Enzymatica AB: ColdZyme blockerar även omikronvarianterna BA.4 och BA.5 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-16 | Enzymatica | Enzymatica AB: ColdZyme also blocks omicron variants BA.4 and BA.5 | Pressreleaser | Ladda ner | Visa Stäng |
|